Corporate Snapshot: Hanall Biopharma’s Recent Market Performance
Trading Activity
On Thursday, 22 April 2026, Hanall Biopharma (009420.KS) closed its trading session down 0.36 % at 09:45 AM Central Europe. The current trading price stands at KRW 41,050, a modest dip from the previous close. With a circulating supply of 51 million shares, the market capitalisation sits at approximately KRW 2.1 trillion. In the past 24 hours, roughly KRW 8.4 billion of shares have changed hands.
The company’s recent trajectory has been relatively flat, having traded down 9.9 % since the end of the previous month. Its 200‑day simple moving average (SMA) is positioned at KRW 51,890.75, suggesting a medium‑term bearish bias. Over the past 52 weeks, Hanall Biopharma’s share price has ranged between KRW 32,600 (recorded on 24 Oct 2025) and KRW 73,000 (reached on 27 May 2026).
Comparative Performance of Peer Stocks
| Stock | Symbol | 24‑hour Change | Current Price (KRW) | Market Cap (KRW) | P/E Ratio |
|---|---|---|---|---|---|
| Hyundai Elevator | 017800.KS | –1.73 % | 67,200 | 2.5 trillion | 6.87 |
| Hansol Chemical | 014680.KS | +0.44 % | 218,000 | 2.4 trillion | 15.31 |
| Lotte Shopping | 023530.KS | +0.46 % | 86,100 | 2.5 trillion | 13.34 |
| Nongshim | 004370.KS | –1.34 % | 399,500 | 2.4 trillion | 11.99 |
While Hanall Biopharma’s share price has slipped slightly, its peers have largely stayed within a narrow range of volatility. Two of the four listed stocks—Hansol Chemical and Lotte Shopping—have recorded modest gains, reflecting a generally stable market sentiment for Korean industrial and consumer staples during the same period.
Company Overview
Hanall Biopharma Co., Ltd., headquartered in Seoul, is a South‑Korean pharmaceutical firm that has been in operation since 1973. The company is actively engaged in the research, development, and commercialisation of a diverse pipeline of therapeutic agents. Key assets under development include:
- HL161 – an anti‑FcRn antibody for autoimmune disease management
- HL036 – an anti‑TNF ophthalmic solution targeting dry eye disease
- HL186 / HL187 – anticancer agents for recurrent or intractable malignancies
- HL040 & HL068 – antihypertensive agents for hypertension‑dyslipidemia and hypertension, respectively
- HL018 – a novel anti‑obesity therapy
- IM156 – a cancer‑treating modality
The company is listed on the Korea Exchange (KRX) and maintains a robust R&D pipeline that seeks to diversify its revenue streams across both domestic and international markets. For more detailed information, stakeholders may visit the company’s official website at www.hanall.co.kr .
This article presents a concise, data‑driven overview of Hanall Biopharma’s recent trading performance and its standing within the broader Korean equity landscape. It aims to provide readers with clear, contextual insight into the company’s market dynamics and strategic focus.
